Kura Oncology Stock (NASDAQ:KURA)


ForecastRevenueOwnershipFinancialsChartTranscripts

Previous Close

$16.88

52W Range

$8.17 - $24.17

50D Avg

$19.04

200D Avg

$20.12

Market Cap

$1.36B

Avg Vol (3M)

$531.32K

Beta

0.83

Div Yield

-

KURA Company Profile


Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; and tipifarnib, an orally bioavailable inhibitor of farnesyl transferase that is in Phase II clinical trials for the treatment of solid tumors and hematologic indications. The company has a clinical collaboration with Novartis to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression or PIK3CA mutation and/or amplification. Kura Oncology, Inc. was founded in 2014 and is headquartered in San Diego, California.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

142

IPO Date

Sep 16, 2015

Website

KURA Performance


KURA Financial Summary


Dec 23Dec 22Dec 21
Revenue---
Operating Income$-165.80M$-140.62M$-131.82M
Net Income$-152.63M$-136.07M$-129.91M
EBITDA$-164.96M$-139.87M$-131.26M
Basic EPS$-2.08$-2.03$-1.96
Diluted EPS$-2.08$-2.03$-1.96

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts


Q2 24Aug 09, 24 | 2:07 PM
Q1 24May 02, 24 | 12:00 AM
Q4 23Feb 27, 24 | 10:19 PM

Peer Comparison


TickerCompany
GRCLGracell Biotechnologies Inc.
ZNTLZentalis Pharmaceuticals, Inc.
KALVKalVista Pharmaceuticals, Inc.
KNSAKiniksa Pharmaceuticals, Ltd.
VRDNViridian Therapeutics, Inc.
MRUSMerus N.V.
LRMRLarimar Therapeutics, Inc.
DAWNDay One Biopharmaceuticals, Inc.
ERASErasca, Inc.
CERECerevel Therapeutics Holdings, Inc.
COGTCogent Biosciences, Inc.
REPLReplimune Group, Inc.
SNDXSyndax Pharmaceuticals, Inc.
INZYInozyme Pharma, Inc.
CRNXCrinetics Pharmaceuticals, Inc.
GLUEMonte Rosa Therapeutics, Inc.
DSGNDesign Therapeutics, Inc.
PTGXProtagonist Therapeutics, Inc.